Welcome to our dedicated page for MESOBLAST SEC filings (Ticker: MESO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MESOBLAST's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MESOBLAST's regulatory disclosures and financial reporting.
Mesoblast Limited reports early real-world experience and commercial rollout of its FDA-approved cell therapy Ryoncil for children with steroid‑refractory acute graft‑versus‑host disease. Among the first 25 patients treated after launch, 21 were alive after completing the 28‑day course, an 84% survival rate. Access efforts include a MyMesoblast patient hub, onboarding of 45 U.S. transplant centers toward a target of 64 centers covering 94% of transplants, and payer coverage reaching more than 260 million U.S. lives. Mesoblast plans a pivotal adult SR‑aGvHD trial with the NIH‑funded BMT‑CTN expected to begin site enrollment this quarter and is also developing its stromal cell platform for additional inflammatory and cardiovascular indications.
Mesoblast Limited submitted a foreign issuer report describing an action first disclosed on the Australian Securities Exchange. On December 17, 2025, the company lodged an Appendix 3G with the ASX, which relates to a new issue announcement and the issue, conversion or payment up of unquoted equity securities. This Appendix 3G document is attached to the report as an exhibit and is incorporated by reference for further details.
Mesoblast Limited furnished a Form 6-K to provide investors with Australian Securities Exchange materials. The filing attaches two ASX documents dated October 28, 2025: an Appendix 3Y change of director’s interest notice and an Appendix 3G notification of issue, conversion or payment up of unquoted equity securities, incorporated by reference as Exhibits 99.1 and 99.2.
This update is administrative, making the ASX disclosures available to U.S. investors under the Exchange Act.
Mesoblast Limited furnished a Form 6-K to provide investors with its Australian Securities Exchange Appendix 4C quarterly report for the quarter ended September 30, 2025. The Appendix 4C is attached as Exhibit 99.1 and incorporated by reference. The filing is an administrative submission linking U.S. investors to the company’s ASX quarterly cash flow and activities report.
Mesoblast Limited Schedule 13G/A filed for ordinary shares/ADRs reports that Gregory George, his sons James and Grant George, and G to the Fourth Investments, LLC collectively hold substantial positions as of September 11, 2025. Gregory George is reported as beneficial owner of 275,851,734 shares in the aggregate (21.59% of the 1,277,782,187 outstanding shares), including 137,123,887 shares he solely owns and discretionary voting or dispositive authority over additional shares held by G to the Fourth Investments and by his sons. G to the Fourth Investments, LLC holds 126,727,847 shares (9.92%). James George and Grant George each report 6,000,000 shares (0.47% each). The filing states the holdings were not acquired to change or influence control.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer for August 2025. The company furnished to U.S. investors an Australian Securities Exchange press release and an investor presentation dated August 29, 2025, attaching them as Exhibits 99.1 and 99.2 by reference.
Mesoblast is a commercial-stage biotech focused on allogeneic mesenchymal lineage cell therapies. The company received FDA approval in December 2024 for remestemcel-L (Ryoncil®) to treat steroid-refractory acute graft-versus-host disease in pediatric patients and launched the product in March 2025. Since launch through June 30, 2025, Mesoblast reported net product sales of $11.3 million.
The company reported a net loss of $102.1 million for the year ended June 30, 2025 and cumulative losses of $1,010.9 million since inception. At June 30, 2025 Mesoblast held $161.6 million in cash and reported net cash usage from operations of $50.0 million for the year. Management states current cash plus forecasted Ryoncil® revenue are sufficient to meet operating cash needs for the next 12 months, and they expect to refinance existing borrowings within that period. The company remains dependent on third-party manufacturers, certain single-source suppliers and successful commercialization, and highlights multiple operational, regulatory and market risks that could affect future results.